Avadel Pharmaceuticals provides update on LUMRYS launch performance

Launch Progress Through December 31, 2023: Greater than 1,900 patients enrolled in Avadel’s RYZUP patient support services: More than 1,000 patients initiated therapy. The majority of RYZUP enrollments and patients currently being treated with LUMRYZ are patients who switched from first generation oxybates, with the balance made up of patients who previously tried and discontinued a first generation oxybate and patients who are new to oxybate treatment.Signed contract with Emisar; Contracts now in place with all 3 PBM owned GPOs; LUMRYZ moved to preferred status within the CVS commercial formularies and Optum Select as of January 1, 2024. Nearly 1,800 health care providers have completed the LUMRYZ REMS certification process, including both experienced oxybate prescribers as well as providers who have never previously prescribed an oxybate.